Responses
Late-Breaking Abstracts
Clinical Trials Complete
948 Final results from AIPAC: A phase IIb comparing eftilagimod alpha (a soluble LAG-3 protein) vs. placebo in combination with weekly paclitaxel in HR+ HER2- MBC
Compose a Response to This Article
Other responses
No responses have been published for this article.